MRI Scans to Study Heart Tissue After Heart Procedures
Studies whether heart MRI findings can help predict problems after stents or bypass surgery.
Plain-language title generated from the registry record
Registry title: STICH3C Cardiac Magnetic Resonance Observational Study
Key facts
- Where
- Calgary, Québec, and Toronto, CanadaSee the 3 sites
Where in Canada
- Libin Cardiovascular InstituteCalgary, CanadaTaking people
- Universite Laval Quebec (CRIUCPQ) CanadaQuébec, CanadaTaking people
- Sunnybrook Health Sciences CentreToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Weill Medical College of Cornell University
- Trial code
- NCT07133984
- Record updated
- 21 September 2026
- Original description
STICOS will test the hypothesis that residual jeopardized myocardium, late gadolinium enhancement, and non-ischemic substrate after revascularization is associated with postoperative adverse cardiovascular events such as heart failure , readmission, or death.Read full original descriptionShow less
STICH3C Cardiac Magnetic Resonance (CMR) Observational Study (STICOS)
STICOS will test the hypothesis that residual jeopardized myocardium, late gadolinium enhancement, and non-ischemic substrate after revascularization is associated with postoperative adverse cardiovascular events such as heart failure , readmission, or death.
This study will look at whether certain heart tissue abnormalities seen on MRI scans can help predict serious health problems after heart procedures like stents or bypass surgery.
Inclusion: Men and women ≥ 18 years old; LVEF ≤ 40% (quantified by echo, single-photon emission computed tomography [SPECT], or CMR within 2 months of enrollment); Prognostically important CAD: either multivessel CAD (triple vessel or double vessel CAD including left anterior descendant artery (LAD), significant coronary stenosis defined as ≥ 70% based on coronary angiography, fractional flow reserve (FFR) ≤ 0.80 or instantaneous wave-free ratio (iFR) ≤ 0.89) or left main disease (+/- other CAD) for which significant stenosis defined as > 50% based on coronary angiography, intravascular ultrasound (IVUS) minimum luminal area [MLA] value ≤ 6.0 mm2 (< 4.5 mm2 Asian descent), or equivalent optical coherence tomography (OCT) measurements; Either planned CABG/PCI within 3 months or CABG/PCI within the last 9 months.
Exclusion: Concomitant valve disease or other condition (e.g., LV aneurysm) requiring surgical repair or replacement; Contraindication to CMR (i.e. magnetically activated materials), gadolinium, regadenoson/adenosine/dipyridamole; Active neoplasm and/or severe end-organ dysfunction with expected life expectancy less than 5 years; -.